electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
4.880
-0.160 (-3.17%)
At close: Oct 30, 2025, 4:00 PM EDT
4.920
+0.040 (0.82%)
After-hours: Oct 30, 2025, 5:10 PM EDT
electroCore Revenue
electroCore had revenue of $7.38M in the quarter ending June 30, 2025, with 20.23% growth. This brings the company's revenue in the last twelve months to $27.70M, up 30.16% year-over-year. In the year 2024, electroCore had annual revenue of $25.18M with 57.09% growth.
Revenue (ttm)
$27.70M
Revenue Growth
+30.16%
P/S Ratio
1.50
Revenue / Employee
$379,452
Employees
73
Market Cap
39.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ECOR News
- 7 days ago - electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025 - GlobeNewsWire
- 27 days ago - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms - GlobeNewsWire
- 4 weeks ago - electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium - GlobeNewsWire
- 5 weeks ago - electroCore's Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire's 2025 Sleep Awards - GlobeNewsWire
- 7 weeks ago - Ecora Resources PLC (ECOR:CA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board - GlobeNewsWire
- 2 months ago - electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief - GlobeNewsWire